Cellid Co. Ltd

Cellid Co., Ltd. develops immunotherapeutic vaccines for cancer and infectious disease therapies. Its pipeline includes BVAC-C for cervical, head and neck, anal, and genital cancers associated with human papilloma virus infection; BVAC-B for stomach, breast, and ovarian cancer targeting the HER-2/neu antigen; and BVAC-P for prostate cancer, renal cell cancer, and glioblastoma targeting prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. The company is also developing BVAC-M for cancers such as melanoma, using GP100/MAGE-A3 antigens, as well as BVAC-Neo. Cellid Co., Ltd. was founded in 2006 and is headquartered in Seoul, South Korea.